For the many affected by chronic skin conditions such as atopic dermatitis and acne, the toll these conditions can take on them and their families is immeasurable.
With an extensive brands portfolio, Menarini Asia-Pacific markets a wide range of branded pharmaceutical, biotechnology, medical device and consumer health brands across key markets in Asia-Pacific. Building on our strengths in Dermatology, Select Specialty Care, Consumer Health, where we have experienced impressive success in these therapeutic fields, Menarini Asia-Pacific is now extending its offerings to include the following therapeutic fields: Men's Health, Cardiovascular and Allergy / Respiratory.
- Nebilet® Nebilet® is a third-generation, highly cardioselective beta-blocker indicated for the treatment of hypertension and heart failure. It combines high beta-1 receptor selectivity with nitric oxide mediated effects to extend benefits beyond blood pressure control.
- Zofenopril® Zofenopril® is a highly lipophilic angiotensin-convertingenzyme (ACE) inhibitor with rapid oral absorption and long duration of action. Its cardioprotective properties provide excellent efficacy in the treatment of hypertension and has been clinically proven to reduce combined incidence of mortality and severe heart failure in patients post myocardial infarction.
- Ranexa® Ranexa® is a novel antianginal agent that provides symptomatic relief in patients with chronic stable angina. It inhibits the late sodium current during ventricular depolarization. This mechanism contributes to a reduction in intracellular sodium and, therefore, a reduction in intracellular calcium, reducing ischemic injury. Ranexa has been clinically proven to reduce the frequency of angina attacks and increase exercise tolerance without producing clinically meaningful changes in heart rate or blood pressure.